Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia

doi:10.1038/s41598-018-19616-3

. 2018 Jan 18;8(1):1099.

doi: 10.1038/s41598-018-19616-3.

Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia

Affiliations

¹ Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX, USA. achaftar@mdanderson.org.
³ Emergency Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 29348438
PMCID: PMC5773566
DOI: 10.1038/s41598-018-19616-3

Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia

Hanine El Haddad et al. Sci Rep. 2018.

. 2018 Jan 18;8(1):1099.

doi: 10.1038/s41598-018-19616-3.

Authors

Affiliations

¹ Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX, USA. achaftar@mdanderson.org.
³ Emergency Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 29348438
PMCID: PMC5773566
DOI: 10.1038/s41598-018-19616-3

Erratum in

Author Correction: Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia.
El Haddad H, Chaftari AM, Hachem R, Michael M, Jiang Y, Yousif A, Raad S, Jordan M, Chaftari P, Raad I. El Haddad H, et al. Sci Rep. 2018 Apr 19;8(1):6258. doi: 10.1038/s41598-018-24172-x. Sci Rep. 2018. PMID: 29674672 Free PMC article.

Abstract

In this analysis, we identified febrile cancer patients with documented infections or neutropenia, whose procalcitonin levels are low at baseline or decrease on antibiotics. These patients had similar outcomes in terms of mortality and relapse of infection regardless of the duration of antimicrobial therapy (less or more than 7 days).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Cited by

Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma.
Knoll BM, Ahmed J, Karass M, Aujla A, McHale P, Kretschmer P, Mazumder A, Seiter K, Ahmed T, Lim SH. Knoll BM, et al. Am J Hematol. 2019 Mar;94(3):E74-E76. doi: 10.1002/ajh.25378. Epub 2018 Dec 31. Am J Hematol. 2019. PMID: 30549311 Free PMC article. No abstract available.
Clinical Characteristics and Associated Factors of Mortality in Febrile Neutropenia Patients; a Cross Sectional Study.
Hatamabadi H, Arhami Dolatabadi A, Akhavan A, Safari S. Hatamabadi H, et al. Arch Acad Emerg Med. 2019 Jul 27;7(1):39. eCollection 2019. Arch Acad Emerg Med. 2019. PMID: 31555769 Free PMC article.
Biomarkers for early complications post hematopoietic cell transplantation: Insights and challenges.
Balakrishnan B, Kulkarni UP, Pai AA, Illangeswaran RSS, Mohanan E, Mathews V, George B, Balasubramanian P. Balakrishnan B, et al. Front Immunol. 2023 Feb 2;14:1100306. doi: 10.3389/fimmu.2023.1100306. eCollection 2023. Front Immunol. 2023. PMID: 36817455 Free PMC article. Review.
Standardizing Febrile Neutropenia Management: Antimicrobial Stewardship in the Hematologic Malignancy Population.
O'Horo JC, Marcelin JR, Abu Saleh OM, Barwise AK, Odean PM, Rivera CG, Tande AJ, Wilson JW, Osmon DR, Tosh PK. O'Horo JC, et al. J Oncol Pract. 2019 Sep;15(9):e843-e848. doi: 10.1200/JOP.18.00775. Epub 2019 Jul 19. J Oncol Pract. 2019. PMID: 31322989 Free PMC article.
Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation.
Bansal A, Jeyaraman P, Gupta SK, Dayal N, Naithani R. Bansal A, et al. Am J Blood Res. 2020 Dec 15;10(6):339-344. eCollection 2020. Am J Blood Res. 2020. PMID: 33489442 Free PMC article.

See all "Cited by" articles

References

1. Dela-Pena, J. et al. Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention. Infect Control Hosp Epidemiol, 1–7, 10.1017/ice.2016.261 (2016). - PubMed
1. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2006;42(Suppl 2):S82–89. doi: 10.1086/499406. - DOI - PubMed
1. Huttner A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2:31. doi: 10.1186/2047-2994-2-31. - DOI - PMC - PubMed
1. Bouadma L, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet (London, England) 2010;375:463–474. doi: 10.1016/S0140-6736(09)61879-1. - DOI - PubMed
1. Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evidence-based child health: a Cochrane review journal. 2013;8:1297–1371. doi: 10.1002/ebch.1927. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Dela-Pena, J. et al. Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention. Infect Control Hosp Epidemiol, 1–7, 10.1017/ice.2016.261 (2016). - PubMed

[2] Dela-Pena, J. et al. Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention. Infect Control Hosp Epidemiol, 1–7, 10.1017/ice.2016.261 (2016). - PubMed

[3] Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2006;42(Suppl 2):S82–89. doi: 10.1086/499406. - DOI - PubMed

[4] Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2006;42(Suppl 2):S82–89. doi: 10.1086/499406. - DOI - PubMed

[5] Huttner A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2:31. doi: 10.1186/2047-2994-2-31. - DOI - PMC - PubMed

[6] Huttner A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2:31. doi: 10.1186/2047-2994-2-31. - DOI - PMC - PubMed

[7] Bouadma L, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet (London, England) 2010;375:463–474. doi: 10.1016/S0140-6736(09)61879-1. - DOI - PubMed

[8] Bouadma L, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet (London, England) 2010;375:463–474. doi: 10.1016/S0140-6736(09)61879-1. - DOI - PubMed

[9] Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evidence-based child health: a Cochrane review journal. 2013;8:1297–1371. doi: 10.1002/ebch.1927. - DOI - PubMed

[10] Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evidence-based child health: a Cochrane review journal. 2013;8:1297–1371. doi: 10.1002/ebch.1927. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia

Affiliations

Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Erratum in

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources